EXACT Sciences — Corporate Update (January 2016)
36 slides from EXACT Sciences's corporate update, Jan 11, 2016
Slide 1: Safe Harbor statement
Safe Harbor statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended that are intended to be covered by the "safe harbo
Slide 2: Safe Harbor statement
Safe Harbor statement Certain statements made inthis presentation contain forward-looking statements within the mearing of Section 27A of the Securities Act of 1933, as. ‘amended, and Section 21E of the Securities and Exchange Act of 1934, as amended that are intended to be covered by the “safe harb
Slide 3: Our Mission
OUR MISSION To partner with healthcare providers, payers, patients & advocacy groups to help eradicate colon cancer 4
Slide 4: Colon cancer: America's second deadliest cancer
Source: American Cancer Society, A Cancer Journal for Clinicians 2016; all figures annual Colon cancer: America’s second deadliest cancer new diagnoses in 2015 132,700 deaths in 2015 49,700 134,490 new diagnoses 49,190 deaths 5 15,690 26,120 41,780 40,890 49,190 158,080 Esophageal Prostate Pancreas
Slide 5: Most preventable, yet least prevented form of cancer
10+ years Sources: J Natl Cancer Inst. 2009; 101:1225-1227 (Itzkowitz) Gastro 1997;112:594-692 (Winawer) Why is colon cancer the “Most preventable, yet least prevented form of cancer”? Pre-cancerous polyp Four stages of colon cancer 6
Slide 6: Detecting colorectal cancer early is critical
Sources: SEER 18 2004-2010 American Cancer Society, Cancer Facts & Figures 2015; all figures annual Detecting colorectal cancer early is critical 9 out of 10 survive 5 years Diagnosed in Stages I or II Diagnosed in Stage IV 7 1 out of 10 survive 5 years 60% of patients are diagnosed in stages III-IV
Slide 7: America's stagnant colon cancer screening rate
8 America’s stagnant colon cancer screening rate Source: CDC NHIS survey results as published in the CDC’s MMWR between 2006 and 2015 50% 52% 59% 58% 80% 80% 2005 2008 2010 2013 2018 2020
Slide 8: Cologuard: Addressing the colon cancer problem
Cologuard: Addressing the colon cancer problem Stool DNA test: 11 biomarkers (10 DNA & 1 protein) FDA-approved & covered by Medicare List price - $649; Medicare rate - $509 Results of 10,000-patient prospective trial published in New England Journal of Medicine Included in American Cancer Society gu
Slide 9: Cologuard's performance confirmed in recent study
*Clean colons have no need for a biopsy Sources: Imperiale TF et al., N Engl J Med (2014) Mayo Clinic Proceedings, Oct 2015 Cologuard’s performance confirmed in recent study Cancer detection 92% (60/65) 100% (10/10) Precancer detection 42% (321/757) 41% (31/76) Specificity (clean colon*) 90% (4002/4
Slide 10: New modeling supports Cologuard's use
11 New modeling supports Cologuard’s use every 3 years 3 years cervical cancer 3 years 2 years breast cancer Source: Clinical Colorectal Cancer, December 2015 Cologuard’s cost-effectiveness compares favorably with established screening strategies $11,313 p er QALY $15,500 per QALY $30,000 per QALY
Slide 11: Exact Sciences Labs: A facility delivering results
Exact Sciences Labs: A facility delivering results Capable of processing >1 million Cologuard tests annually 12
Slide 12: 24/7/365 nationwide colon cancer screening network drives compliance
Only 24/7/365 nationwide colon cancer screening network drives compliance Patients Doubling compliance through direct engagement Physicians Easing burden of colon cancer screening follow-up Payers Maintaining metrics to support 3-year adherence 71% Patient compliance* *Patient compliance rate: numbe
Slide 13: A multi-billion dollar U.S. market opportunity
A multi-billion dollar U.S. market opportunity Potential 80M-patient U.S. screening market* Total U.S. market opportunity for Cologuard $4B*** Unscreened** 24M patients 30% Colonoscopy & FOBT 32M patients 40% Cologuard 24M patients 30% *80 million average-risk, asymptomatic people ages 50-84 **Assum
Slide 14: Three-pronged commercial strategy
Three-pronged commercial strategy Physicians Patients Payers Public relations Multi-channel direct to consumer Primary care sales force Medical education Digital campaign Clinical & health publications Market access team Guidelines Targeted TV test 15
Slide 15: Cologuard's growing physician penetration
Cologuard’s growing physician penetration Adding ~2,000 ordering physicians per month 16 *IMS data based on heart drug prescriptions August 2014 December 2015 4,100 8,300 14,700 21,000 27,000 200,000 potential Cologuard prescribers* Q1 2015 Q2 2015 Q3 2015 Q4 2015
Slide 16: Strong customer satisfaction with Cologuard
17 Strong customer satisfaction with Cologuard Physicians expectations met or exceeded 98% Patients rated Cologuard experience very positive 88% Sources: ZS survey conducted for Exact Sciences, n=300 Exact Sciences Laboratories patient satisfaction survey data is cumulative; n = 2,799
Slide 17: Early results illustrate Cologuard's impact
Source: Imperiale TF et al., N Engl J Med (2014) Exact Sciences internal estimates based upon prevalence and detection rates from DeeP-C study Early results illustrate Cologuard’s impact Cancers potentially detected by Cologuard 104,000 Completed Cologuard tests >600 Cancers >500 Early-stage cancers
Slide 18: Increasing America's screening population
Increasing America’s screening population 49% screened with colonoscopy Screening history of Cologuard users 42% never screened before Source: Colorectal Cancer Screening with Multi-target stool DNA-based Testing Previous Screening History of the Initial Patient Cohort, poster presented at American
Slide 19: Completed Cologuard tests continue growing
Completed Cologuard tests continue growing Completed Cologuard tests Guidance Guidance 2015 2016 20 4K 11K 21K 34K 38K Q4 2014 Q1 2015 Q2 2015 Q3 2015 Q4 2015 104,000 $39 - 39.5M >240,000 $90 - 100M
Slide 20: Strong weekly ordering growth
Strong weekly ordering growth 21 Thanksgiving Christmas & New Years Holiday seasons impact re-orders, returned collection kits 8/10/14 8/24/14 9/7/14 9/21/14 10/5/14 10/19/14 11/2/14 11/16/14 11/30/14 12/14/14 12/28/14 1/11/15 1/25/15 2/8/15 2/22/15 3/8/15 3/22/15 4/5/15 4/19/15 5/3/15 5/17/15 5/31/
Slide 21: Cologuard outpacing blockbuster diagnostic launches
Sources: Cytyc, Digene and Exact Sciences company documents and estimates Cologuard outpacing blockbuster diagnostic launches First-year revenue 1.5x ahead of ThinPrep; 2x ahead of HPV 22 Revenue – launch year $90 – $100M Guidance $40M $33M Y2 Q0 Q1 Q2 Q3 Q4 Cologuard ThinPrep Digene's HPV
Slide 22: Strong Cologuard launch trajectory
Strong Cologuard launch trajectory Strong ordering trend Sales & marketing drove 12% monthly growth Growing customer base 2,000 new physicians per month; 27,000 total 23 Predictable re-ordering Most physicians continue consistently re-ordering Customer satisfaction Very positive Cologuard experience
Slide 23: Value proposition for payers
Quality of care Strategy to advance coverage to contracting Cost savings Member satisfaction Value proposition for payers NEJM publication shows 92% sensitivity Easy, non-invasive test; >70% patient compliance Cologuard delivering positive budget impact 24 $
Slide 24: Expanding Cologuard's coverage for relevant patients
Expanding Cologuard’s coverage for relevant patients Covered, not contracted Covered, in-network contract Sources: US Census, “Health Insurance Coverage Status and Type of Coverage by Selected Characteristics: 2013” US Census, “State Characteristics: Vintage 2013” AIS Directory of Health Plans: 2015
Slide 25: Anthem contract and in-network status will drive adoption
37.6 million covered lives, second largest insurer in U.S. Strong presence in 14 states Largest plan in 6 states Second largest plan in 4 states Anthem enters into agreements by network/region California contract signed January 2016 Seeking 5 agreements in 1H 2016 Parallel implementation of commerci
Slide 26: Focusing product pipeline on targeted opportunities
Focusing product pipeline on targeted opportunities Lung nodules Pancreatic cancer 2H 2016 Clinical need Market opportunity blood pancreatic juice ~1.5M patients/ year* $1.0B+ $0.5B+ 600-700K patients with cysts Type of test 28 Initial data readout Sources: *Silvestri GA et al. A Bronchial Genomic C
Slide 27: Establishing a long-term growth plan
Establishing a long-term growth plan 29 Cologuard Pipeline Lung nodules Pancreatic Leverage existing sales force In-licensing Co-promote Product acquisition
Slide 28: Establishing a long-term growth plan
Establishing a long-term growth plan Pipeline = Lung nodules = Pancreatic Leverage existing sales force = In-licensing = Co-promote = Product acquisition Cologuard 29
Slide 29: Appendix
APPENDIX 31
Slide 30: Financial highlights
Financial highlights* *Exact Sciences has not completed preparation of its financial statements for the year. These estimates are based on preliminary, unaudited data. Actual results may differ. 32 Preliminary Q4 ‘15 revenue $14.0 – 14.5 million Preliminary FY ’15 revenue $39.0 – 39.5 million 104,00
Slide 31: Cologuard usage mirrors the overall screening market
Cologuard usage mirrors the overall screening market 33 Sources: CDC NHIS 2013 survey and BRFSS 2012 Survey. Berger et al., ACG Poster (2015) Note: CDC considers colonoscopy within 10 years and FOBT within 1 year as up-to-date. Cologuard Screening History does not involve a time component, so the FO
Slide 32: Cologuard potential of a primary care provider
Cologuard potential of a primary care provider 34 200k Primary care providers actively seeing patients 50+ based on heart drug prescriptions (IMS) 400 Patients per doctor 133 Targeted Cologuard patients (33% penetration of patients) 45 Annual Cologuard tests per provider with a 3 year interval 80M A
Slide 33: Breakdown of current U.S. insurance market
Breakdown of current U.S. insurance market Aetna Anthem Cigna UnitedHealthcare Traditional Medicare 32% 46% Medicare 46% Commercial mercial - All others 24% Medicare Advantage 14% Military/ Medicaid 8% 35 Source: AIS Directory of Health Plans: 2015; ages 50-84
Slide 34: CISNET modeling highlights Cologuard 3-year benefits to harms ratio
Zauber A, et. al. “Evaluating the Benefits and Harms of Colorectal Cancer Screening Strategies: A Collaborative Modeling Approach.” AHRQ (2015). See Appendix Tables 3(a) – 10(c). CISNET modeling highlights Cologuard 3-year has best benefits to harms ratio 36
Slide 35: CISNET modeling suggests Cologuard screening strategy is effective
Impact of U.S. Preventive Services Task Force CISNET modeling suggests Cologuard screening strategy is effective Source: Zauber A, et. al. “Evaluating the Benefits and Harms of Colorectal Cancer Screening Strategies: A Collaborative Modeling Approach.” AHRQ (2015). See Appendix Tables 3(a) – 10(c).
Slide 36: CISNET modeling suggests Cologuard screening strategy is effective
CISNET modeling suggests Cologuard screening strategy is effective Median USPSTF model output for screening patients 50-85 with Cologuard every 3 years e@est 37